NCT05051553View on ClinicalTrials.gov

A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

December 23, 2021

Study Completion Date

April 8, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Fedratinib

Specified dose on specified days

Trial Locations (1)

33136

Syneos Health Clinical Research Services, Llc, Miami

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05051553 - A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants | Biotech Hunter | Biotech Hunter